De novo designed transmembrane peptides activating the α5β1 integrin.

Area of Science:

• Biochemistry
• Molecular Biology
• Biophysics

Background:

• Transmembrane α-helical peptides (CHAMP) are used to study integrin activation by disrupting helix-helix interactions.
• Previous work utilized CHAMP peptides to probe integrins αIIbβ3 and αvβ3.

Purpose of the Study:

• To extend CHAMP peptide design to inhibit the association of integrin α5β1 transmembrane domains.
• To target the Ala-X3-Gly motif within the α5 integrin subunit.

Main Methods:

• Utilized a computational design algorithm and a new workflow within the Rosetta molecular modeling suite.
• Tested peptide activation of integrins α5β1 and αVβ3 in human endothelial cells.
• Employed solution-state nuclear magnetic resonance to determine peptide binding to integrin transmembrane domains.

Main Results:

• CHAMP peptides were designed and synthesized targeting the α5β1 integrin.
• Peptides activated integrin α5β1 but not αVβ3 in human endothelial cells.
• One peptide preferentially bound the β1 transmembrane domain, while another showed modest binding to both α5 and β1 domains.

Conclusions:

• Novel CHAMP peptides were characterized that activate integrin α5β1.
• These peptides can serve as valuable reagents for investigating integrin biology, despite not fully achieving the initial inhibition goal.
• The study highlights the utility of computational design in creating tools for membrane protein research.